EP Patent

EP3242689A1 — Cnp prodrugs

Assigned to Ascendis Pharma Endocrinology Division AS · Expires 2017-11-15 · 9y expired

What this patent protects

The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.

USPTO Abstract

The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.

Drugs covered by this patent

Patent Metadata

Patent number
EP3242689A1
Jurisdiction
EP
Classification
—
Expires
2017-11-15
Drug substance claim
No
Drug product claim
No
Assignee
Ascendis Pharma Endocrinology Division AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.